{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.4","upperLimit":"6.2","value":"3.0"},{"comment":"NA: The upper limit of the Confidence Interval could ne be reached because there were not enough events to estimate the time to the later events.","groupId":"OG001","lowerLimit":"1.0","upperLimit":"NA","value":"2.9"},{"groupId":"OG002","lowerLimit":"2.3","upperLimit":"5.2","value":"2.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"115"}],"units":"Participants"}],"description":"PFS is the time from date of CTL019 infusion to the date of first documented disease progression or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US.","id":"OG000","title":"Tisagenlecleucel - Main Cohort"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Fraunhofer Institut für Zelltherapie, Leipzig, Germany.","id":"OG001","title":"Tisagenlecleucel - Cohort A"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at a US facility and an EU facility (Fraunhofer Institut für Zelltherapie, Leipzig, Germany).","id":"OG002","title":"Tisagenlecleucel - All Patients"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS): Comprised all patients who received infusion of tisagenlecleucel.","reportingStatus":"POSTED","timeFrame":"up to approx. 61 months","title":"Progression Free Survival (PFS) Per Independent Review Committee","type":"SECONDARY","unitOfMeasure":"Months"}